Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Webster

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Medicinal Chemistry|May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA HelicaseJustin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
Molecular Cancer Therapeutics|October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4APeggy A Thompson, Boreth Eam, Nathan P Young, et al.
Journal of Medicinal Chemistry|March 13, 2018
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) InhibitionSiegfried H Reich, Paul A Sprengeler, Gary G Chiang, et al.
Journal of Medicinal Chemistry|March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|September 3, 2015
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor AgentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Medicinal Chemistry|May 30, 2020
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA HelicaseJustin T Ernst, Peggy A Thompson, Christian Nilewski, et al.
Molecular Cancer Therapeutics|October 10, 2020
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4APeggy A Thompson, Boreth Eam, Nathan P Young, et al.
Journal of Medicinal Chemistry|March 13, 2018
Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) InhibitionSiegfried H Reich, Paul A Sprengeler, Gary G Chiang, et al.
Journal of Medicinal Chemistry|March 19, 2004
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|September 3, 2015
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor AgentRaj N Misra, Hai-yun Xiao, Kyoung S Kim, et al.
Journal of Medicinal Chemistry|August 23, 2002
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, S David Kimball, Raj N Misra, et al.
Pageof 2